Daiichi Sankyo’s FY2027 revenue exceeds consensus by 10%

Market overview

Daiichi Sankyo’s revenue growth will outpace analyst estimates by at least 10%, driven by continued strong sales of its cancer drug portfolio, particularly Enhertu. This exceeds the consensus midpoint of $22.1B for FY2025.

earnings prediction market

Implied probability (Yes)

70%

Closes

2027-12-31

Source: user-generated

More earnings markets

• Will cash burn exceed $5M in Q4? — 65% Yes
• Will Venyra beat Q4 2026 revenue consensus of $230M? — 85% Yes
• Will Nuburu secure emergency financing by Q3 end? — 35% Yes
• Will Everpure, Inc. report a non-GAAP EPS beat for the quarter ended June 30, 2026? — 50% Yes
• Will KR miss Q4 operating margin guidance? — 65% Yes
• Will George Risk report Q4 2026 revenue above $13M? — 85% Yes
• Will DCI beat Q4 EPS consensus of $0.88? — 65% Yes
• Will inventory days decrease below 70 by year-end? — 40% Yes

Browse all earnings markets →